Literature DB >> 10936882

Link between heart disease, cholesterol, and Alzheimer's disease: a review.

D L Sparks1, T A Martin, D R Gross, J C Hunsaker.   

Abstract

Increased prevalence of Alzheimer's disease-like beta-amyloid deposits in the neuropil and within neurons occurs in the brains of non-demented individuals with heart disease. Heart disease is a prevalent finding in Alzheimer's disease, and may be a forerunner to the dementing disorder. In the cholesterol-fed rabbit model of human coronary heart disease there is production and accumulation of beta-amyloid in the brain. This accumulation of beta-amyloid can be reversed by removing cholesterol from the rabbits' diet. In culture cells, a cholesterol challenge has been shown to increase production of beta-amyloid, and dramatic reductions of cholesterol produced by HMG Co-A reductase inhibitors decrease production of beta-amyloid. Increased beta-amyloid production is also produced by dietary cholesterol in a number of transgenic mouse models of Alzheimer's disease. Administration of HMG Co-A reductase inhibitors may block beta-amyloid production caused by dietary cholesterol in rabbits. Clinical trials testing the benefit of HMG Co-A reductase inhibitors in the treatment of Alzheimer's disease are underway. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936882     DOI: 10.1002/1097-0029(20000815)50:4<287::AID-JEMT7>3.0.CO;2-L

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  37 in total

1.  Oxidative stress impairs learning and memory in apoE knockout mice.

Authors:  Marianne Evola; Allyson Hall; Trevor Wall; Alice Young; Paula Grammas
Journal:  Pharmacol Biochem Behav       Date:  2010-05-08       Impact factor: 3.533

2.  Drug discovery for Alzheimer's disease: the end of the beginning.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Aggregation of vascular risk factors and risk of incident Alzheimer disease.

Authors:  J A Luchsinger; C Reitz; L S Honig; M X Tang; Steven Shea; R Mayeux
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

4.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

5.  Localization of the noncovalent binding site between amyloid-beta-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry.

Authors:  Fotini N Bazoti; Jonas Bergquist; Karin Markides; Anthony Tsarbopoulos
Journal:  J Am Soc Mass Spectrom       Date:  2008-04-08       Impact factor: 3.109

6.  Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure.

Authors:  Michael L Alosco; Mary Beth Spitznagel; Lawrence H Sweet; Richard Josephson; Joel Hughes; John Gunstad
Journal:  Pacing Clin Electrophysiol       Date:  2014-12-10       Impact factor: 1.976

Review 7.  Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism.

Authors:  Walter J Lukiw; Miguel Pappolla; Ricardo Palacios Pelaez; Nicolas G Bazan
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

8.  Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat.

Authors:  Ann-Charlotte Granholm; Heather A Bimonte-Nelson; Alfred B Moore; Matthew E Nelson; Linnea R Freeman; Kumar Sambamurti
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

9.  Classical conditioning of the rabbit's nictitating membrane response is a function of the duration of dietary cholesterol.

Authors:  Bernard G Schreurs; Carrie A Smith-Bell; Deya S Darwish; Goran Stankovic; D Larry Sparks
Journal:  Nutr Neurosci       Date:  2007 Jun-Aug       Impact factor: 4.994

10.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.